Mary Wojnaroski

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Congenital Heart Disease

Drug Administration

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Anne T Berg, Natasha N Ludwig, Mary Wojnaroski, Chere A T Chapman, Rebecca Hommer, Gabrielle Conecker, JayEtta Z Hecker, Jennepher Anne Downs
FDA Patient-Focused Drug Development Guidances. Neurology 102 (1) (2023)
Anne T Berg, Natasha N Ludwig, Mary Wojnaroski, Chere A T Chapman, Rebecca Hommer, Gabrielle Conecker, JayEtta Z Hecker, Jennepher Anne Downs
FDA Patient-Focused Drug Development Guidances: Considerations for Trial Readiness in Rare Developmental and Epileptic Encephalopathies Neurology 102 (1) (2023)
Anne T Berg, Natasha N Ludwig, Mary Wojnaroski, Chere A T Chapman, Rebecca Hommer, Gabrielle Conecker, JayEtta Z Hecker, Jennepher Anne Downs
FDA Patient-Focused Drug Development Guidances: Considerations for Trial Readiness in Rare Developmental and Epileptic Encephalopathies Neurology 102 (1) (2023)
Anne T Berg, Natasha N Ludwig, Mary Wojnaroski, Chere A T Chapman, Rebecca Hommer, Gabrielle Conecker, JayEtta Z Hecker, Jennepher Anne Downs
FDA Patient-Focused Drug Development Guidances. Neurology 102 (1) (2023)
Anne T Berg, Natasha N Ludwig, Mary Wojnaroski, Chere A T Chapman, Rebecca Hommer, Gabrielle Conecker, JayEtta Z Hecker, Jennepher Anne Downs
FDA Patient-Focused Drug Development Guidances: Considerations for Trial Readiness in Rare Developmental and Epileptic Encephalopathies Neurology 102 (1) (2023)
Anne T Berg, Natasha N Ludwig, Mary Wojnaroski, Chere A T Chapman, Rebecca Hommer, Gabrielle Conecker, JayEtta Z Hecker, Jennepher Anne Downs
FDA Patient-Focused Drug Development Guidances: Considerations for Trial Readiness in Rare Developmental and Epileptic Encephalopathies Neurology 102 (1) (2023)